Route of Administration Segment Analysis: Topical (Largest Segment) vs Parenteral (Fastest-Growing Segment)

The topical route of administration segment dominated the psoriasis treatment market with a share of 58.94% in 2026. Its leadership is primarily attributed to its widespread use as a first-line treatment option for patients with mild to moderate psoriasis. Topical therapies offer targeted treatment directly at affected skin sites, enabling symptom management while minimizing systemic exposure. Their accessibility, ease of application, and suitability for long-term disease management have supported broad adoption across patient populations, reinforcing the segment’s dominant position.

The parenteral route of administration segment is emerging as the fastest-growing category due to the increasing use of advanced biologic therapies for moderate to severe psoriasis cases. Healthcare providers are increasingly turning to injectable treatments that offer targeted immune system modulation and improved disease control for patients who do not respond adequately to conventional therapies. Growing awareness of biologic treatment options and continued advancements in immunology-based therapeutics are contributing to the rapid expansion of this segment.

Type Segment Analysis: Plaque Psoriasis (Largest Segment) vs Psoriatic Arthritis (Fastest-Growing Segment)

Plaque psoriasis held the largest share of the psoriasis treatment market in 2026. The segment’s dominance is driven by the high prevalence of this disease type compared to other forms of psoriasis. Characterized by raised, inflamed skin lesions, plaque psoriasis often requires ongoing therapeutic intervention, creating sustained demand for a broad range of treatment options. Increased diagnosis rates, growing patient awareness, and the availability of multiple therapeutic approaches continue to support the segment’s leading position.

The psoriatic arthritis segment is expected to witness the fastest growth as greater attention is being directed toward the management of psoriasis-related joint complications. Improved recognition of the connection between skin symptoms and musculoskeletal disorders has encouraged earlier diagnosis and treatment. The expanding availability of targeted therapies capable of addressing both dermatological and joint manifestations is further driving growth in this segment.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest & Fastest-Growing Segment)

In the psoriasis treatment market, the hospital pharmacies segment held the dominant position and was also the fastest-growing distribution channel in 2026. The segment benefits from the increasing use of specialized and prescription-based therapies that often require administration, monitoring, or consultation within hospital settings. Hospital pharmacies play a critical role in ensuring access to advanced treatments, particularly biologics and other high-value medications used in the management of moderate to severe psoriasis. Its continued growth is supported by the expanding role of hospitals in comprehensive psoriasis care, including diagnosis, treatment planning, and long-term disease monitoring. As healthcare systems increasingly emphasize integrated care pathways and access to specialized therapies, hospital pharmacies remain a central distribution channel for psoriasis medications, strengthening both their market share and growth prospects.